



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/620,039	07/16/2003	Arun Srivastava	44141-034RI	8203
7590	09/12/2005		EXAMINER	
Kenneth L Cage McDermot Will & Emery 600 13th Street NW Washington, DC 20005-3096			WHITEMAN, BRIAN A	
			ART UNIT	PAPER NUMBER
			1635	

DATE MAILED: 09/12/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/620,039	SRIVASTAVA, ARUN 3
	Examiner	Art Unit
	Brian Whiteman	1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

**A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM
THE MAILING DATE OF THIS COMMUNICATION.**

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 14 June 2005.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 16-30 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 16-30 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____.
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: _____.

DETAILED ACTION

Non-Final Rejection

Claims 16-30 are pending.

Applicant's traversal and the amendment to the specification filed on 6/14/05 is acknowledged and considered by the examiner.

In view of the new grounds of rejection, the finality of that action is withdrawn.

Specification

The disclosure is objected to because of the following informalities: This application contains sequence disclosures that are encompassed by the definition for nucleotide sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with requirements of 37 CFR 1.821 through 1.825 because a sequence is listed in the specification (Figure 1A-1B), but the SEQ ID NO (SEQ ID NO: 1) for the sequence is not listed in the Figure or in the specification under description of drawings for Figure 1.

Appropriate correction is required.

The amendment filed 6/14/05 proposes amendments to the specification that do not comply with 37 CFR 1.173(b), which sets forth the manner of making amendments in reissue applications. A supplemental paper correctly amending the reissue application is required. Deletions must be shown by brackets and not strike through.

Claim Objections

Claim 18 is objected to because of the following informalities: the phrase “SEQ ID NO: 1 comprises” is grammatically incorrect. Suggest amending the phrase to recite: -- SEQ ID NO: 1 that comprises” --. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 16-30 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Upon further consideration of the claims, the limitation ‘wherein each of said inverted terminal repeats is SEQ ID NO: 1’ in claim 16 and claims dependent therefrom is not supported by the as-filed specification. There does not appear to be a written description of the limitation in the application as filed. See MPEP § 2163.06. It appears that the limitation was added to the claims to overcome the prior art teaching an inverted terminal repeat comprising SEQ ID NO: 1. Applicant cites col. 9, lines 41-45 for support of the limitation. However, col. 9, lines 41-45 specifically recites: In a preferred embodiment, the AAV ITRs comprise the 145 nucleotides as shown in FIG. 1. Fragments which contain the 125 nucleotides which form the palindromic

hairpin (nucleotides 1-125 of FIG. 1) or longer fragments which contain the terminal 191 nucleotides of the viral chromosome are also useful." This would indicate to the skilled artisan that the specification has written support for an ITR comprising SEQ ID NO: 1 and does not provide written support for not only of SEQ ID NO: 1. The instant specification provides written support for the ITR comprising SEQ ID NO: 1, but does not provide written support for limiting the ITR to SEQ ID NO: 1 (ITR consisting of SEQ ID NO: 1).

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claim 20 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term "heterologous gene encodes a non-biologically functional protein" in claim 20 is a relative term, which renders the claim indefinite. The term "heterologous gene encodes a non-biologically functional protein" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The metes and bounds of the term are not defined because a gene encodes a functional protein and the specification or the prior art does not teach a gene encoding a non-biologically functional protein.

Applicant's arguments filed 6/14/05 have been fully considered but they are not persuasive.

In response to applicant's argument that in view of col. 7, lines 15-19 of the instant specification the term is clear to those skilled in the art, the argument is not found persuasive because the specification does not define the metes and bounds of the term. Col. 7, lines 15-19 specifically recite: "For example, a hybrid gene comprising a various domains and functions from a variety of sources can be designed and produced by recombinant technology or enzymatic or chemical synthesis." A non-biologically functional protein would not have a function as defined in the specification.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764. The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, acting SPE – Art Unit 1635, can be reached at (571) 272-0811.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST).

Art Unit: 1635

The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Brian Whiteman
Patent Examiner, Group 1635

JOSEPH WOITACH, PH.D.
PRIMARY EXAMINER
Joe Wotach
AU 1632